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planning CT and CBCT were matched on bony structures after 
automatic semi-rigid fusion alongside the 3 axis : xbone, ybone, zbone, 2) 
planning CT and CBCT were matched on the prostate with respect to 
intra-prostatic markers: xsoft, ysoft, zsoft. The position of the prostate 
within the pelvis for each pre- and post-treatment study points was 
defined as xpros= (xbone – xsoft), ypros= (ybone – ysoft) and zpros= (zbone – zsoft).  
Rectum and bladder were outlined on each CBCT with the aim to 
assess changes in rectal or vesical repletion during each fraction. 
Organ distension was assessed by measuring the average rectal cross-
sectional area (rCSA; defined as the rectal volume divided by length), 
and the area of the bladder when evaluated 2.5cm above the prostate 
base (A-blad) on pre- and post-treatment CBCT. 
Results: Two hundred and ninety four CBCT were reviewed for this 
analysis. The average fraction duration was shorter with IMAT than 
with IMRT (4'49'', vs. 11'00'', p< 0.001). During fractions of IMRT the 
prostate showed statistically significant shifts in the longitudinal (p= 
0,049) and lateral (p=0,013) axis while it was not statistically 
significant during fractions of IMAT. Intra-fraction rCSA increased 
neither during IMAT nor IMRT whereas A-blad increased only during 
fractions of IMRT but with no correlation with prostate displacements. 
Conclusions: The prostate moves within the pelvis during an IMRT 
course which could lead to a greater daily geographic miss when 
compared to the IMAT technique.  
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Purpose/Objective: To present an innovative approach based on the 
methods of Artificial Intelligence (AI) to better predict N status in 
prostate cancer patients (pts), integrating some important clinical and 
therapeutic parameters (Gleason Score/sum, age, initial PSA, 
neoadjuvant or neoadjuvant/ concomitant hormonal therapy vs no 
hormonal therapy), known before radiotherapy (RT).  
Materials and Methods: A total of 1808 pts from a National Italian 
multicentric database was analyzed. Following the D’Amico criteria, 
we found 317 'low risk', 577 'intermediate risk' and 914'high risk' pts. 
with a known N status at diagnosis. N+pts were defined as those with 
a positive contrast enhanced pelvic MRI and/or CT scan; those showing 
a nodal only relapse after RT were also classified as N+ (as none of 
them received pelvic RT). Finally, 6/317 (1.9%), 10/577 (1.7%), 
39/914 (4.2%) such 'N+' pts were found. Using the Roach formula 
(2/3*PSA + ([Gleason-6] x 10) with a cut-off of>15%, >10% and >5%, the 
individual risk of nodal involvement was calculated. Finally, 3 AI 
classifications method, based on decision trees (the J48 method, the 
Forrest Tree method and the Random Tree method) combined with 3 
techniques of manipulation of imbalanced samples (oversampling, 
undersampling and combined under/ oversampling) were used to 
predict the N status. The accuracy of the Roach formula was 
calculated. 
Results: Table 1 resumes the performances of the Roach formula and 
of the 3 AI methods. All the proposed AI methods taking in account 
more clinical and therapeutic features perform better than the Roach 
formula. Looking at the whole population, the classic approach 
showed an accuracy (i.e. true positives + true negatives/whole 
population) rate ranging, depending on the cut-off, between 34.6% 
and 56.5%. In the same population, the 3 AI methods showed an 
accuracy rates ranging between 76.3% and 98.2%.  
For the low, intermediate and high risk patients, accuracy of the AI 
ranged between 16.7% - 99.4%, 65%-99.5% and 75.6%-98.7%. These 
methods always performed better than the Roach formula. 
The Random Forest method, combined with the Oversampling 
technique is the best method, with specificity, sensibility, and 
accuracy rates of 100%, 96.9% and 98.2%, respectively. 
Conclusions: Roach formula's is suboptimal in predicting the nodal 
status of prostate cancer patients. Non-linear relationships with more 
than two variables probably exist. New approaches taking into 
account more variables could possibly better predict the nodal status 
of the patients. 
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Purpose/Objective: In April 2010 the prospective observational study 
started with the aim of developing predictive models of genito-urinary 
(GU) toxicity and erectile dysfunction for prostate cancer patients 
(pts) treated with high dose radiotherapy (RT) delivered with 
conventional (1.8-2Gy/fr, CONV) or moderately hypo-(2.5-2.7Gy/fr 
HYPO) fractionation. In this ad-interim analysis the correlation 
between dosimetry/clinical factors and the modifications between 
pre-RT(IPSSbasal) and final (IPSSend) IPSS values were investigated. 
Materials and Methods: For all pts several clinical factors were 
collected as: T stage, hormonal therapy, smoking, use of drugs, 
presence of concomitant pathologies, previous surgery, age. Bladder 
parameters were also recovered: volume, D1%, mean dose, DVH and 
Dose Surface Histogram (DSH) in absolute and in relative value, 
referred to both the whole treatment and to the weekly delivered 
treatment (DVHw/DSHw, expected to be more predictive of acute 
symptoms). DSH were calculated using a dedicated software (Vodca, 
MSS Inc.). IPSSend≥15 was considered as end-point. Logistic uni- and 
backward multi-variate (MVA) analyses were performed. Sub-analyses 
were repeated in two selected subgroups: (1) pts with IPSSbasal<15 
(2) pts in the HYPOarm. 
Results: At the time of analysis (November 2012), 212 pts were 
available; full 3D dose-volume data were available for 177/212 (73 
CONV and 104 HYPO). IPSSend≥15 were 56/212 (26%). The dosimetry 
factors more predictive were assessed by looking to the most 
significant differences between DSH/DVH (DVHw/DSHw) of pts with 
IPSSend≥ or <15. Best predictors were the absolute bladder surface 
≥8.5Gy/week and ≥12.5 Gy/week; the correlation was also significant, 
although lower, for absolute DVHw and % DSHw/DVHw. In Fig1 the 
mean DSHw for pts with IPSSend ≥ and <15 are shown (HYPO group). 
The correlation was stronger for the HYPO group. Total DVH/DSH were 
not correlated with IPSSend≥15. At MVA (p<0.0001), the main 
independent predictors of IPSSend≥15 were: baseline IPSS (OR:1.19, 
p<0.001), S12.5w(abs) (OR:1.04, p=0.005); S8.5w(abs) (OR:1.01, 
p=0.13); use of anti-hypertensive (OR:2.08, p=0.058). The predictive 
value of the model was relatively high (AUC=78.2%, CI:71-84%).The 
independent role of S8.5w and S12.5w was confirmed when excluding 
pts with baseline IPSS≥15 (AUC=76.6%) and in the HYPO sub-group 
(AUC=76.2%).  
Fig.1 The average of DSHw for pts with IPSSend ≥ and <15. 
 
  
Conclusions: Absolute weekly DSH/DVH predicts the risk of 
IPSSend≥15 together with basal IPSS and the use of anti-hypertensive. 
The correlation was confirmed if excluding pts with large basal IPSS 
and in the HYPO subgroup. To our knowledge, this result represents 
the first evidence of a dose-volume/surface effect for acute GU 
symptoms prospectively measured in an observational study. The 
inclusion of HYPO pts likely enhanced the effect, due to the 
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treatment acceleration, as measured by weekly dose-volume/surface 
parameters. 
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Purpose/Objective: Although there are data suggesting that whole-
pelvic radiotherapy (WPRT) might improve cancer-specific survival in 
selected patients, a clear benefit has not been demonstrated yet. 
Randomized controlled trials designed to solve this question are 
urgently warranted. One of the obstacles in the treatment decision 
making process is the lack of accurate staging modalities to diagnose 
lymph node (LN) involvement so that until now, only an extended LN 
dissection ensures a full nodal staging. The objective of this study was 
to investigate the feasibility and efficacy of a sentinel node (SN) 
procedure in patients at high risk for LN involvement and to illustrate 
the impact of using this procedure in the design of a WPRT trial. 
Materials and Methods: A total of 74 patients with a risk ≥10% but 
<35% for LN metastases (Partin tables) who were node-negative (N0) 
at contrast-enhanced CT, were prospectively enrolled. Three 
transrectal 99mTc-nanocolloid injections were performed per prostate 
lobe under ultrasound guidance. Two hours later, patients underwent 
planar and SPECT imaging to facilitate localisation of the SN during 
surgery. Intraoperatively, a gamma probe was used to detect the LN 
that had taken up the radionuclide. SN were removed separately. 
After SN dissection, all patients underwent a super-extended LN 
dissection (internal, external and common iliac, obturator fossa and 
presacral regions), followed by radical prostatectomy. All retrieved LN 
were histopathologically examined. 
Results: In total, 470 SN were scintigraphically detected (patient 
median, IQR 3-9) of which 371 (patient median 4, IQR 2.25-6) were 
located and removed. In 1 patient, no SN were detected on the SPECT 
images nor intraoperatively and in 2 patients, the SN that were found 
on the SPECT images could not be retrieved during surgery.  
Histopathology confirmed LN metastases in 34 patients (46%) with a 
total of 91 affected LN (median number per patient 2, IQR 1-3) of 
which 46 LN were SN (51%). Twenty-seven of these node positive (N+) 
patients had at least 1 N+ region containing a SN, which was affected 
in 96% of the cases (26/27). However, the 6 additional N+ patients in 
whom no SN were detected in the affected region had to be taken 
into account as false negatives (FN). Therefore, sensitivity of the 
procedure decreased to 79% (26/33). If this procedure would be 
applied to select patients for a WPRT trial, no less than 21% of the N+ 
patients would not be randomized. Moreover, since SN procedure 
alone removed all affected LN in 14/33 (42%) patients, these ‘new N0’ 
patients should be taken into account for sample size calculation. 
Conclusions: Although the SN procedure was technically feasible, its 
sensitivity was too low to offer a valuable alternative to the standard 
extended LN dissection for nodal staging in these high-risk PCa. If this 
procedure would be applied to select patients for a WPRT trial, FN 
rate and the number of N0-patients due to the SN procedure should be 
taken into account.  
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Purpose/Objective: For prostate cancer patients with a large rectum 
at planning a risk of geometric miss has been suggested in recent 
literature. We also previously reported a significant decrease in tumor 
control in case of a large rectum at planning for intermediate- to 
high-risk prostate cancer patients. Now we investigated in the same 
patient group with a prolonged median follow-up of 110 months, 
whether a large rectum at planning was associated with local failure, 
regional/distant failure, and/or prostate cancer related death (PCRD), 
and to what extent this affected overall survival. 
Materials and Methods: Patients from a multicenter trial (randomized 
between 78 Gy and 68 Gy) with data on acute diarrhea and with an 
estimated seminal vesicle involvement of >25 % were included 
(n=349). Planning target volume was the prostate and seminal vesicles 
with a margin of 1 cm for the first 68 Gy and a margin of 5 mm for the 
10 Gy boost when applicable with 0 mm margin towards the rectum. 
Investigated risk factors for geometric miss were (similar to our 
previous study): rectal volume ≥90 cm3 and diarrhea reported during 
at least 25% of treatment (RF1, n=87/349), and cross-sectional area 
(CSA) of the rectum >8 cm (RF2, n=83/349) regardless reported 
diarrhea. CSA was calculated by dividing the rectal volume by the 
rectal length in cranial-caudal direction. We calculated Hazard Ratios 
(HR) and Kaplan Meier curves for each outcome, stratifying for the 
dose arms. 
Results: There were 68 cases of PRCD, 26 cases of local failure as first 
event, and 73 cases of regional/distant failure as first event. 
Surprisingly, there was no increased risk for local failure (Figure) for 
both risk factors (HRs≈1) while they were associated with a higher risk 
of regional/distant failure (Figure): HR=1.6 (p=0.06) for RF1 and 
HR=2.0 for RF2 (p=0.007), and with increased rates of PCRD: HR=1.9 
(p=0.01) and HR=1.7 (p=0.04), respectively. The estimated difference 
in disease specific survival was 14% at 10 years (Figure) for RF1 (68 % 
versus 82 %). The corresponding overall survival curve showed a 
difference of only 6 % at 10 years (60 % versus 66 %).  
 
  
Conclusions: Patients with a large rectum at planning had no 
increased risk for local failure, which considerably weakens the 
hypothesis of 'geometric miss'. Apparently the local tumor was not 
missed during treatment. An alternative hypothesis for the observed 
increase in regional/distant failure could be that a large rectum at 
planning is associated with geometrical miss outside the prostate, i.e. 
extraprostatic disease in -for instance- lymph node areas receiving 
less (unintended) dose due to a ventral shift of the dose distributions.  
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Purpose/Objective: Several reports have suggested an impact of 
treatment parameters such as radiation dose, treatment margin and 
image guidance (IG) of radiotherapy (RT) delivery on Prostate Cancer 
(PCa) treatment outcomes. The purpose of this work is to review 
published actuarial estimates of Prostate Specific Antigen Relapse 
Free Survival (PRFS) for high-risk disease treated by 3DCRT, IMRT or 
IG-IMRT with or without Androgen Depravation Therapy (ADT), and 
establish the dose-response relationship.  
Materials and Methods: PubMed searches were performed on PCa 
outcomes following external beam RT. Data on treatment margin, use 
and duration of ADT, prescribed radiation dose, treatment 
technique(IMRT/IGRT), randomized trial, PRFS (Phoenix definition) at 
3, 4, 5 and 7-years for high risk PCa were collected. Dose per fraction 
was corrected to 2 Gy-equivalent doses using an α/β of 1.4. In order 
to limit the uncertainty of the procedure, only trials with moderate 
fractionation were included (3.1Gy/fr. or less). A funnel plot was used 
to investigate publication bias. A multivariate analysis of the 
parameters were performed to clarify if data from all studies could be 
pooled (p-values <0.05 were considered significant). A logistic 
regression curve was fitted to the PRFS and dose data at each time 
point. The gradient (γ50) and the dose required to obtain 50% PRFS 
